digipharm

DIGIPHARM

The world population is so high and the diseases plaguing man today is becoming very worrisome which makes it very imperative that health care is improved upon so that people (patients) can have direct access to health services. But unfortunately, the services are limited as the flaws that associate the current global health care infrastructure results in so much inefficiency, wastage and sub-optimal health outcomes.

Statement of the Problem

Digipharm aim to utilize innovative block chain technology to overcome barriers to patient’s access and good pricing, reduction in cost for stakeholders and avoid some other limitations to health care delivery. The main objective of the Digipharms is to be the leading pioneer of value-based health care delivery, innovative evidence generation and patient empowerment across the health care industry.

What is the Problem to be Addressed in the Digipharm?

Digipharm has always been confronted with some barriers which include

· Problem of reimbursement

· Delay in red world evidence (RWE)

· Insights

ProposedSolution

Despite the problems confronting the Digipharm such as pricing difficulty and delay in real world evidence, the firm still has outstanding records. For example, the digitization of healthcare is a key element to improving patient outcomes, their quality of life and reducing the intense burden on health systems worldwide. Strange diseases prevalent in the world today has forced the Digipharmy to bring about value based care. These improved pattern of innovative pricing. Results in personalized medicine. Digipharm understand the importance and necessity of value-based healthcare, within such a dynamic environment following the efforts of the Digipharm towards personalized medicine, the firm goes ahead topromote the development of a health information infrastructure that is transparent and security conscious.

Again, cost effectiveness is another target of the Digipharm. With cost effectiveness, uncertainties about drugs efficacy is eliminated. This is because a drug can be so effective, yet the price can still very low. Findings show that in 2010–2011, the price value of certain products varies directly proportional to the value of the product which is the real target of the digpharm.Digipharmhas the style of using the reimbursement platform to harness the beneficial textures of automated smart contracts allowing the fed time application of dynamic pricy models and patient access schemes between health care providers, payers and manufactures. Reimbursement platform also allows the implementation of several pricing conditions within the some agreements using smart contract technology, thus providing flexible and personalized pricing solution while by passing the currently associated infrastructural banners. The dynamic nature of reimburse platform will further permit health care systems and manufactures to manage and monitor their budgets more effectively.

The platform empower payers to negotiate careful pricing agreements. It also expedite integration, co-ordination, delivery of patient centric health care systems with a view on improving patient outcomes.

On the while reimbursement promotes faster access to Digipharm product, cost effectiveness is assured. Red tapism is reduced and data security is ensured. The platform hopes to provide wider range of therapies.

Model Solutions on the Insights

The insights platform creates benefit for based care.

Ø It promotes the ability to access up-to-date and reliable health information.

Ø It promotes the ability to conduct pragmatic clinical trials cheaply and efficiently.

Ø It enhances the ability to provide greats quality of care under the umbrella of a value-based delivery system.

It should be noted that the private block chain technology is the anchor of the Digipharm. The choice of the block chain is as a result of the following reasons

a) Security

b) Confidentiality

c) Scalability

d) Smart contract execution

Competition

Digipharm has other firms that compete with them since there are several issues confronting the health care delivery. These problems include

· Fragmented health care system

· Inability to track patient adherence in real time

· Patient privacy concerns

· Inconsistent practices between health care providers

With the above problem at head which brings about stiff competition, there is urgent need to ensure accelerated access of products.

While drugs with accelerated approval enter the market with FDA approval, payers are still required to assess whether and how these drugs should be paid for stiff competition has necessitated drive towards personalized healthcare, supported by genomic profiling with genomic profiling uncertainties around clinical efficacy is well reduced.

THE TEAM

Road Map:

please visit the whitepaper

All software development at Digipharmfollows the secure development lifecycle. Digipharmenforce compliance with industry best practices at all stages of development and code is tested for vulnerabilities before it is shipped to production. Security is an integral part of development at all its seven stages:

1. Training

2. Requirement its

3. Implementation

4. Verification

5. Revenge

6. Response.

Digipharm tokens (DPH)

DPH will be used to pay fees on Digipharm platform. Access fees will be determined and stipulated in USD value and the quantity of tokens needed will depend on the type of access combined with the form of interaction needed. It has the following characteristics DPH supply, ticker code, decimal places, token price.

DPH Token Sale Information

In Digipharm, for presale 15,000,000 DPH

For main sale 50,000,000DPH

Funding Usage and Token Distribution

In DPH, the hierarchy is as follows

Charity foundation -0.5%

Marketing — 4%

Legal -15%

Professional services -15.5%

Product development -65%

In terms of distribution

Referrals -1%

Reserve -14%

Team — 20%

ICO — 65%.

 for information

Whitepaper: https://digipharm.ch/docs/DigipharmWP.pdf

Website: https://www.digipharm.ch/

Facebook: https://www.facebook.com/digipharmteam/

Twitter: https://twitter.com/DigipharmTeam